- |||||||||| [VIRTUAL] PERSISTENT MIXED CHIMERISM WITHOUT RELAPSE IN CHILDREN AFTER HSCT FOR HEMATOLOGIC MALIGNANCY (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1627;
Further study is needed to determine what factors can predict which patients with mixed chimerism will remain in remission in order to avoid the morbidity associated with DLI. Notably, the two patients who had distinction of their cells had mixed chimerism of their myeloid compartment, which may have allowed them to maintain suppression of their leukemia with a combination of NK and T lymphocytes.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Review, Journal: Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia. (Pubmed Central) - Feb 6, 2020 CAR T therapy uses genetically modified autologous T cells directed against CD19, a known target on B cells. CRS and neurological symptoms, formally termed as immune-effector-cell-associated neurological syndrome, have been described along with hypogammaglobulinemia, cytopenias, and infections.
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Clinical, Review, Journal: CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. (Pubmed Central) - Feb 6, 2020 Eighty percent of inotuzumab-treated B-ALL patients may achieve a CR state. This review is focused on the biological and clinical activities of CD22 antibodies in B-ALL, and provides evidence about the potential role played by qualitative and quantitative analysis of the CD22 molecule on individual B-ALL blasts in predicting the depletion of leukemic cells, and, ultimately, leading to better clinical response rates.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Pathologic Findings in Patients with Refractory B-Lymphoblastic Leukemia Treated with Blinatumomab (LACC 403 A) - Jan 24, 2020 - Abstract #USCAP2020USCAP_702; Patients treated with blinatumomab and with refractory B-lymphoblastic leukemia show a propensity for recurrence in unusual extramedullary sites. Interestingly, these extramedullary recurrences occur in the setting of negative bone marrow biopsies, exhibit retention of surface expression of CD19, and do not show an association with specific cytogenetic abnormalities.
- |||||||||| Decadron (dexamethasone) / Merck (MSD), Blincyto (blinatumomab) / Astellas, Amgen
Clinical, Journal: Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease. (Pubmed Central) - Jan 21, 2020 Over the next two months, the patient received six doses of triple intrathecal chemotherapy (cytarabine, methotrexate, and hydrocortisone), three concurrently with continuous blinatumomab in the second month...Unfortunately, the patient eventually expired after further relapse approximately one year later. To our knowledge, this is the first published case report of severe neurotoxicity in a patient who was given blinatumomab concurrently with intrathecal chemotherapy.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB, Oncaspar liquid (pegaspargase) / Takeda
Updates in Acute Lymphoblastic Leukemia: Pediatric, Young Adult, Adult (Ballroom BC) - Jan 14, 2020 - Abstract #HOPA2020HOPA_81; It is important that pharmacists are familiar with indications for appropriate use, dosing strategies, monitoring, and toxicity management of available asparagine depleting enzymes. Learning Objectives: Recognize definition of pediatric, young adult, and adult patients with ALL and corresponding risk factors Identify toxicities of pegaspargase therapy and propose monitoring plans based on patient characteristics Analyze the data supporting the use of blinatumomab and inotuzumab for relapsed/refractory disease and minimal residual disease positive ALL Recommend maintenance tyrosine kinase inhibitor therapy in patients after HSCT based on patient and disease characteristics
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Blinatumomab in Ph-like Acute Lymphoblastic Leukemia – an Institutional Experience (World Center Marriott - Palms & Cypress Foyers) - Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_967; Ph-like ALL patients are more likely to remain MRD-positive after induction therapy (Jain et al, Blood 2017); utilizing blinatumomab as frontline or for MRD in first CR may improve outcomes. Further investigation with larger sample size and multi-center experience is required to fully determine the efficacy and role of blinatumomab, other immunotherapies, and allo-HSCT in the treatment of Ph-like ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 7, 2020 P1, N=44, Suspended, Further investigation with larger sample size and multi-center experience is required to fully determine the efficacy and role of blinatumomab, other immunotherapies, and allo-HSCT in the treatment of Ph-like ALL. Trial primary completion date: Dec 2019 --> Dec 2020
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Taking a "BiTE out of ALL" - Blinatumomab approval for MRD positive ALL. (Pubmed Central) - Dec 25, 2019 MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial suspension: A041703: Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 23, 2019 P2, N=64, Suspended, However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL. Recruiting --> Suspended
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Journal: Study of aromatic profile of different crosses of Monastrell white wines. (Pubmed Central) - Dec 19, 2019 The present study reports the first investigation of the volatile composition and sensory characteristics of directed crosses white wines obtained from Monastrell and other varieties, such as Cabernet Sauvignon, Syrah, Tempranillo and Verdejo. The results obtained indicate that the use of some of these white crosses could be a good option for growing them in this Mediterranean area as a result of the contribution of a good quality in the wine aroma.
|